evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

10 questions · 10 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3 · 30%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 50%Moderate 2 · 20%High 0 · 0%

Combined immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Overall survival (OS) · People with advanced non‐small cell lung cancer

Combined immune checkpoint inhibitors (ICIs) probably leads to lower overall Survival (OS) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Combined immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer

Combined immune checkpoint inhibitors (ICIs) showed no clear difference in adverse Events grade 3 to 4 compared with chemotherapy (low certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Overall survival (OS) · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) probably leads to lower overall survival (OS) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Progression‐free survival · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to lower progression‐free survival (PFS) compared with chemotherapy (low certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Overall response rate (ORR), · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to higher overall response rate (ORR) compared with chemotherapy (low certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to lower adverse Events grade 3‐4 compared with chemotherapy (low certainty).

1 finding from 1 review

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

QoL · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to higher QOL‐C30 GHS/QOL (range 0‐100) ‐ change from baseline to week 15 compared with chemotherapy (low certainty).

1 finding from 1 review